Elanco Compound definition

Elanco Compound means a single Active Ingredient directly resulting from a Development Program that is selected by Elanco for further development for commercialization as a Product, and as to which [*] in accordance with Section [*].
Sample 1Sample 2
Elanco Compound means any one or more of [***] (as specifically defined in Exhibit B to this Agreement), or (ii) any polypeptides made in the Design & Development Program that are modifications or derivatives of a molecule described in part (a) of this definition. The Parties may mutually agree in writing to add additional development targets to the Design & Development Program, in which event “Elanco Compounds” shall also include such additional development targets and modifications and derivatives thereof made in the Design & Development Program.
Sample 1Sample 2
Elanco Compound means any one or more of (i) Certain Non-Human Polypeptides, or (ii) RDBV(s), all for use in the Field and were made pursuant to the Design and Development Program, or by or for Elanco after the expiration or termination of the Design and Development Program, said Certain Non-Human Polypeptides or RDBV’s having been made to contain a non-naturally encoded amino acid, and having completed an in vivo study in a target animal species. The Parties hereby acknowledge that, except for New Elanco Compounds according to Section 5.2(c), no target loading payments are required by Elanco as part of the election of additional Elanco Compounds as stated in Amendment No. 3 to the Collaboration, Research & License Agreement.
Sample 1Sample 2

Examples of Elanco Compound in a sentence

  • For the sake of clarity, the milestone payment listed above is payable only once per Elanco Compound.

  • If the exclusive license for any Elanco Compound or Product in the New Projects group has irrevocably reverted pursuant to Section 5.2(b) or Section 4.9(e), then Elanco may from time to time submit to Ambrx a written request for the Steering Committee to add a then-newly-discovered molecule in the Field as an additional Elanco Compound (a “New Elanco Compound”).

  • For clarity, “currently in development or commercialization” of any individual Elanco Compound or Product as described in the previous sentence will be deemed to have occurred upon completion of an in vivo study in a target animal species using such Elanco Compound; or if any such Elanco Compound or Product has received Regulatory Agency approval.

  • Parties will allow Regulatory, Quality Assurance, Quality Control, Accounting and Legal personnel from either Party or its attorneys, advisors, accountants and contractors timely and reasonable access to audit financial records, trial protocols, pilot scale manufacturing documents, procedures manuals, patent documents and other Active Ingredient, Elanco Compound or Product-related items relating to the license granted by Scynexis pursuant to this Agreement.

  • In further consideration of the license granted by Scynexis under Article 2 of this Agreement, Elanco shall make one-time payments within [*] of [*]: [*] [*] [*] [*] For the sake of clarity, the milestone payment listed above is payable only once per Elanco Compound.

  • The Development Program will be conducted by the Research Team in accordance with the Development Plan and will more fully describe the work to be pursued by Scynexis and Elanco during each Program Year to develop the information necessary for Elanco to make an Elanco Compound Selection in accordance with 4.2(a).

  • The Development Plan shall provide high level guidance as to the types of information necessary for Elanco to consider making an Elanco Compound Selection.

  • All Know-How, including, but not limited to, manufacturing information, formulation development, marketing authorizations, including the veterinary master file and any foreign equivalents, developed by or on behalf of Elanco after Elanco’s selection of an Elanco Compound pursuant to section 4.8 shall be owned by Elanco.

  • In further consideration of the license granted by Scynexis under Article 2 of this Agreement, upon [*], Elanco shall make a one-time payment in the sum of (i) [*] for each [*] Elanco Compound [*], within [*] of attainment of such milestone; or (ii) [*] for each [*] Elanco Compound [*], within [*] of attainment of such milestone (“Development Milestone”).

  • In addition, with respect to the [ * ] under the Product Development Plan, if Elanco wishes to maintain its exclusive license rights to Product(s) in the Field in the Territory, Elanco will pay to Anacor not more than [ * ] days following Elanco’s making a positive Development Decision for an Elanco Compound in the [ * ] a one-time, non-refundable, non-creditable payment of [ * ].


More Definitions of Elanco Compound

Elanco Compound means any one or more of (a) [***] (as specifically defined in Exhibit B to this Agreement), (b) any polypeptides made in the Design & Development Program that are modifications or derivatives of a molecule described in part (a) of this definition, or (c) [***] through 12/31/2009 as specifically defined in Exhibit B to this Agreement. The Parties may mutually agree in writing to add additional development targets to the Design & Development Program, in which event “Elanco Compounds” shall also include such additional development targets and modifications and derivatives thereof made in the Design & Development Program.
Sample 1
Elanco Compound means (a) a Candidate Compound [ * ] directly resulting from the Design & Development Program that is selected by Elanco for development and commercialization as a Product following a Development Decision, and (b) the [ * ] Backup Compounds [ * ] to such selected compound that are selected pursuant to Section 4.8. Subject to Section 2.9, Elanco Compounds shall not include (i) any compound that is subject to an option or license granted by Anacor to a Third Party prior to the Effective Date, (ii) any of the compounds referred to by Anacor as [ * ], and all backup compounds thereto, (iii) [ * ], (iv) any compound useful for treating, diagnosing or preventing [ * ], unless agreed otherwise by Anacor and (v) any [ * ], unless agreed otherwise by Anacor. [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. First AMENDMENT to the COLLABORATIVE RESEARCH, LICENSE & COMMERCIALIZATION AGREEMENT “[ * ]” means a fixed dose [ * ] as may be included by the Parties pursuant to Section 5.7(a), provided that, a [ * ].
Sample 1
Elanco Compound means one or more active ingredients directly resulting from Lipid Sciences Technology that is selected by Elanco for development and commercialization of Product(s) and/or New Product(s).
Sample 1

Related to Elanco Compound

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Lead Compound means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid a quantity soluble lead compound exceeding, when calculated as lead monoxide, five percent of the dry weight of the portion taken analysis.

  • Licensed Compound means [***].

  • Back-Up Compound means, with reference to any particular Development Candidate or Drug Product Candidate, a Compound which (a) has the same principal mode of action (i.e., Potentiator or Corrector) as that Development Candidate or Drug Product Candidate; and (b) was among the group of Compounds, identified by VERTEX as potential additional lead molecules having the same principal mode of action, from which the Development Candidate was selected.

  • Licensed Compounds means any EZH2 Compound(s) that is:

  • Compound means the taking of two or more ingredients and fabricating them into a single

  • Product Candidate means each of MYO-101, MYO-102, MYO-103, MYO-201 and MYO-301, as defined on Exhibit B, in each case in any form or formulation.

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Development Candidate means a Compound that meets the Development Candidate Criteria for the initiation of a Development Program for the treatment of CF, and which is the subject of a notice from Vertex to CFFT that Vertex intends to commence formal pre-clinical development of the Compound in the Field pursuant to the provisions of Section 3.1 hereof.

  • Compounds means a small molecule HMT inhibitor.

  • Collaboration Product means any pharmaceutical product in finished form that contains a Collaboration Compound, either as the sole active ingredient or in combination with one or more other active ingredients, and all present and future formulations, dosages and dosage forms thereof.

  • Biosimilar Product means, with respect to a Licensed Product in any country, any biosimilar product sold by a Third Party not authorized by or on behalf of Celgene, its Affiliates or Sublicensees, (a) that is a biosimilar biological product, as defined in 21 USC 379j-51 (or any successor or replacement thereof), a similar biological medicinal product, as defined in Annex I to Directive 2001/83/EC (or any successor or replacement thereof), or any similar biosimilar or generic product under the Laws of any country or jurisdiction, or (b) regarding which Regulatory Approval is obtained by referencing Regulatory Data of such Licensed Product.

  • Diagnostic Product means any test or assay for diagnosing or detecting a disease, disorder, medical condition, or symptom.

  • Covered Product The consumer product that You purchased concurrently with and is covered by this Agreement.

  • Licensed Product means any pharmaceutical product containing a Licensed Compound (alone or with other active ingredients), in all forms, presentations, formulations and dosage forms.

  • GSK has the meaning set forth in the preamble.

  • Hemp product means the same as that term is defined in § 3.2-4112.

  • Biological Samples means any physical samples obtained from Study Participants in accordance with the Protocol for the purposes of the Study.

  • Initial Indication means the use of a Product for the treatment of opioid addiction.

  • Biological product means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein other than a chemically synthesized polypeptide, or analogous product, or arsphenamine or any derivative of arsphenamine or any other trivalent organic arsenic compound, applicable to the prevention, treatment, or cure of a disease or condition of human beings.

  • New Product means the Synology-branded hardware product and Synology-branded accessories contained in the original packaging Customer bought from an authorized Synology distributor or reseller. You may see our “New Product” at Product Support Status.

  • Drug Product means a specific drug in dosage form from a known source of manufacture, whether

  • Drug Substance means an active ingredient that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure or any function of the human body, but does not include intermediates used in the synthesis of such ingredient.